Clinical trial
Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic…
NCT00177242 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00177242 |
|---|---|
| Title | Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma |
| Official title | Phase II Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib |
| Enrollment | 45 |
| Start date | Sep 1, 2004 |
| Completion | Dec 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Jan 18, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: